Pinkerton Retirement Specialists LLC Has $4.26 Million Position in Amgen Inc. (NASDAQ:AMGN)

Pinkerton Retirement Specialists LLC increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 7.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,628 shares of the medical research company’s stock after acquiring an additional 920 shares during the quarter. Pinkerton Retirement Specialists LLC’s holdings in Amgen were worth $4,258,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. United Community Bank bought a new stake in Amgen in the 4th quarter valued at $29,000. Horizon Financial Services LLC bought a new stake in Amgen in the 1st quarter valued at $28,000. nVerses Capital LLC bought a new stake in shares of Amgen during the 2nd quarter valued at $31,000. Bbjs Financial Advisors LLC bought a new stake in shares of Amgen during the 2nd quarter valued at $33,000. Finally, Western Pacific Wealth Management LP bought a new stake in shares of Amgen during the 4th quarter valued at $37,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on AMGN shares. Oppenheimer reiterated an “outperform” rating and set a $380.00 target price on shares of Amgen in a research report on Wednesday, August 7th. Bank of America upped their target price on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Wells Fargo & Company downgraded Amgen from an “overweight” rating to an “equal weight” rating and upped their price objective for the stock from $320.00 to $335.00 in a research report on Wednesday, August 7th. Morgan Stanley dropped their price objective on Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research report on Thursday, July 11th. Finally, Argus upped their price objective on Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Eleven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $327.28.

Amgen Trading Up 0.0 %

Shares of AMGN stock opened at $330.06 on Friday. The stock has a market cap of $177.06 billion, a price-to-earnings ratio of 47.15, a PEG ratio of 2.85 and a beta of 0.61. The stock has a 50-day moving average of $327.75 and a 200-day moving average of $303.32. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64. Amgen Inc. has a 1-year low of $249.70 and a 1-year high of $346.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing the consensus estimate of $5.01 by ($0.04). The company had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The company’s quarterly revenue was up 20.1% on a year-over-year basis. During the same period in the previous year, the company posted $5.00 EPS. On average, equities research analysts forecast that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were paid a dividend of $2.25 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 annualized dividend and a yield of 2.73%. Amgen’s dividend payout ratio is currently 128.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.